Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q4 FY2020 Earnings Presentation
19 slides from Morepen Laboratories's earnings presentation, Jun 22, 2020
Slide 1: Cover letter to stock exchanges: Investors Presentation Q4 FY20
... . *: ~IAOREPEN i~\ORE~EN Date: 22/06/2020 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No : (022) 26598100 - 8114 Phones: 91-22-22721233/4 Fax No:
Slide 2: Investors Presentation (Q4'FY20) June 2020
“ I CHOOSE INVESTORS PRESENTATION (Q4’FY20) JUNE 2020
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Highlights of 12M'FY20
Highlights of 12M’FY20 Consolidated Performance ₹ crores • Net Revenue in FY20 up by 12% at Rs. 862.55 crore as compared to FY19 . • Net Profit before tax up by 34% at Rs. 39.11 crore against Rs.29.18 crores in FY19 . • Cash Profits up by 10% at Rs. 76.02 crore against Rs.69.08 crores in FY19. • API
Slide 5: Highlights of Q4'FY20
Highlights of Q4’FY20 Consolidated Performance ₹ crores • Net Revenue in Q4’FY20 down by 5.2% at Rs. 208.39 crore as compared to Q4’FY19 . • Net Profit before tax up by 6.2% at Rs. 11.36 crore against Rs.10.70 crores in Q4’FY19 . • Cash Profits down by 8.5% at Rs. 19.99 crore against Rs.21.85 crores
Slide 6: Other Highlights
Other Highlights: • Company’s manufacturing facilities remained functional during the lockdown period with limited manpower and have now resumed 80-90% operations, and it may take some time for things to normalize in the marketplace. As offices continue to remain closed, all senior people are workin
Slide 7: Annual Segment wise growth
Annual Segment wise growth: ₹ crores • Overall business for the year (12M’FY’20) has registered growth of 12% as compared to FY19 despite loss of sales in last two weeks of the year on account 863 of the complete lockdown. 11.7% • API Business has grown at 15% for the year FY’20 and still contribute
Slide 8: Q4-Segment wise growth
5.2% Q4-Segment wise growth : ₹ crores • On account of lockdown in the last two weeks of the March’20, most of the business segments were hit, thereby affecting last quarter sales performance for the company. 220 • Overall business for the Quarter (Q4’FY20) has been down at 5.2% as compared to Q4’FY
Slide 9: API: Domestic sale leads the way
API: Domestic sale leads the way API Revenues ₹ crores • API business retains its lion’s share of 61% and has grown at 15% on year–on-year basis despite loss of sales on account of lockdown 473.95 towards the end of March 2020. 15% • Company got license to manufacture Hydro Chloroquine (HCQ) and is
Slide 10: Regulated Markets Exports Spike
Regulated Markets Exports Spike. ₹ crores API Export • Asia pacific Export business has got 51% share in the export business for the year FY’20 and a growth of 6% as compared to FY’19. 10% 341.09 • USA Business has grown by 15%, while Europe market has shown 309.38 an increase of 10% • Other semi-re
Slide 11: Devices Business – Performance
Devices Business – Performance ₹ crores • Home Devices portfolio has achieved remarkable growth during the quarter compared 39.93 to same period last year. In order to fight the Covid-19 battle, company launched Non- 44% Contact Infrared Thermometers in the month of April 2020. 27.77 • Blood Glucose
Slide 12: Prescription drugs sales
Prescription drugs sales Branded Formulations ₹ crores • Branded Prescription (Rx) products has grown by 19% during the year FY’20 with major contribution coming from main brands like Salutm, Rhythmix, Klarim,Qnergy, Bacikid, Metmore , Intebac and Cefopen. In spite of impact of loss of sales due to
Slide 13: OTC Business gains momentum
OTC Business gains momentum ₹ crores • OTC category in total has registered a growth of 31% during the quarter, among 17.78 that Grooming business has achieved a handsome growth of 29% in Q4’FY20 and 58% in FY’20. OTC Business has launched many new products to its Health Basket 31% in the nutritiona
Slide 14: The Joy Of Growing Together
‘The Joy Of Growing Together 13
Slide 15: Standing together with you..
Standing together with you.. 14
Slide 16: Consolidated Net Profit after tax rises
Consolidated Net Profit after tax rises ₹ crores • EBIDTA number has grown up by 10% during the year FY’20 as compared to Net FY’19 . Consolidated Revenue • Cash Profits during the year FY’20 has increased by 10 % as compared to FY’19. 219.7 • Net profit before tax has risen to Rs. 39.11 crores as a
Slide 17: FY20 Performance - Standalone
FY20 Performance - Standalone ₹ crores Y-o-Y Y-o-Y Q4’FY20 Q4’FY19 Growth FY20 ’FY19 Growth Net Revenue 190.87 207.10 (7.8%) 801.40 720.91 11.2% Expenditure 172.80 186.01 (7.1%) 727.52 652.22 11.5% EBIDTA 18.07 21.09 (14.3%) 73.88 68.69 7.6% Interest 0.62 0.92 (32.4%) 1.97 2.07 (5%) Cash Surplus 17.
Slide 18: Q4'FY20 Performance - Consolidated
Q4’FY20 Performance - Consolidated ₹ crores Y-o-Y Y-o-Y Q4’FY20 Q4’FY19 Growth FY20 FY19 Growth Net Revenue 208.39 219.74 (5.2%) 862.55 772.21 11.7% Expenditure 187.78 196.97 (4.7%) 784.55 701.02 11.9% EBIDTA 20.61 22.78 (9.5%) 78.00 71.19 9.6% Interest 0.62 0.93 (33.3%) 1.98 2.11 (6.2%) Cash Surplu
Slide 19: Thank You
Tank Youu Fg MOREPEN The Joy Of Growing Together
Morepen Laboratories — Q4 FY2020 Earnings Presentation on 6ix